Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm seeing nasty reverse splits (plural) in the future.
No name JoeBenson? Sounds like you're being fed bullshit.
There is a lot of selling pressure on this stock.
Looks like life support from any angle.
Any stock can get to $50 with enough reverse splits
"Push the stock price lower?"
Here we go again. So many on this board have been repeating this claim for 3 years now. Over and over and over again whenever bad news makes the stock price fall. It's always somebody else's fault and they're always the victims. Spin it on to everything except the truth. Same old song and dance...paranoia self destoyer.
No shame. Sad to see. Will pump to 0 looks like
A fool and his money soon parted
Can you give us the name of the hedge fund backed by big pharma who is mugging MF? You must know who it is if you're making such a claim.
Oh ok so then why is everyone selling and nobody has been really buying much since the last piece of news.
I have been in stocks, like Mhan in 2009, that was broke, with no product at .001/share that a Nasdaq Bio-tech CEO took over, put 10 Million dollars of cash into, and a drug license from France and it passed $50/share in 2021, Tgtx is the stock. Just for one.
Right know short seller and note conversion MM's are all over the stock since the last PR, and for all we know a Hedge fund backed by Big Pharma is trying to Mug MF into making a dirt cheat JV deal.
I have seen scams, shells with no money, not plan with way higher market caps that $RVVTF.
RVVTF was last reported here to still 2.5 Mil dollars. Most OTC stocks issue trillions of share just to raise 20% of that much cash.
And RVVTF has several pipelines they have data that no one else has on the Phase III drug trial data.
That data may be worth a fortune, for closing a JV deal with firms that are tossing around 100's of Millions of dollars to fund JV's with firms like RVVTF.
If I was one of groups that had put in millions at .50 to .15/share I'd be letting retail fools sell to me and be using hedge fund's MM muggers to milk retail, before the next major news comes out.
Push the stock price lower? What are you talking about? It’s already under 2 cents. Just stop trying to get people invested in here. Only thing that will make this price go up is when frank steps down but he isn’t smart enough to see that he ruined this company single handily.
Ecomike do you really think there is hope here? You have to let us uneducated investors know how this stock can be revived.
Looks like its time for some hospital Chlorox, sanitizer and slime disinfect here, reading the last 2 days of BS attempts to push the stock price lower.
LOL…Yeah MF could be on message boards all day because the evidence shows he certainly is not running the company.
Bucillamine is in final chapter dead. It would be advisable to explore other stocks that align with your investment strategy. BDPT might be a better choice.
The best part is after each 20-30% drop, is the typical posts spinning the bad news into good news and stating how others are interpreting it wrong. Famous words “MMs on the ask”, “Christmas gifts”, “buying all the shares I can”. Can’t forget the bold letters and the words in red. Nothing means business like someone who writes in red and bold!
Can’t forget that at the end of day, the victory of buying shares when it was down 45%, but closed only down 35%! Spin it into some genius decision when he was “swallowing all the shares he can” when the stock was in the .30s and higher.
Feel bad for posters that don’t know better and follow some of these dudes. It’s the only reason why I hope karma is true and comes back to bite them hard. It would be well deserved
Ha. I always maintained EM and MF are one in the same.
Roughly 4 years at 33k per month salary. That comes to about $1,500,000 in his own pocket. Where else did the money go?
Go back to some old posts and see how some on this board completely worshipped him and kissed his feet. You know who you are. Red flags were all over the place and anybody who pointed them out got beaten up. They were 100% dead wrong about everything every step of the way. Thank you for an honest post.
White.... you assessment is "Spot On".
Ya bucillamine 2.0 with what money? Frank pissed all the money away. He had a chance to make this big but he screwed the pooch. Call it like it is. He pissed around early on when he started this trial and had millions of delta patients but didn’t do a thing. Majority of hospitalizations were in the first 200 so what does that tell you? He should have pushed early on but didn’t. Time for the board to get him out for not completing his duty as ceo. But go ahead and defend him and tell everyone how this has so much potential.
Someone who wants to hurt you. Like a narcissist. So many hurt here. SEC should be notified imo
Yep he was wrong 100% of the time. Not even close. What’s even more telling is that he keeps posting on this board as if nothing has happened. What kind of person does that?
And why not. He’s a legend on the board and so many worship him!
When you see the same thing over and over and get the same results you get all the attention
Even if you lead the crowd to thousands of losses some refuse to think for themselves
Thats horrible of course but I speak truth!
That’s some read. Too bad he’s out 6 figures. I still can’t believe no law suits associated with the raise @ .15 just a few months before fda decision to stop the trial.
Still pumping LOL
Looks like our next event will be on nuclear bomb explosion for this company to take off. Scam
Yes you are correct
Sure, after a 1 for 250 R/S. This is what cash strapped penny stocks do to survive who do not have any revenues (sales).
It’s was all a scam look at the pumps
Bucillamine is dead .... over .... just like we all knew months ago. Question is, can this company shift back to being a psychedelic innovator and actually do something. To be honest, based on how bad the CEO effed up the Bucillamine clinical trial, I don't have much faith. Never seen a bigger foul up.
They just did a 4.3 mil raise at .15 valuation
You really think more cash raise is likely?
Only one person on here likely to buy that bs lol
RVVTF has 356 million in O/S and only 2.5M in cash. They are going to need cash. Everyone knows that MF and his insider buddies will never freeze their compensation packages in order to cut the cash burn rate. Diluting to raise cash at these low PPS levels will not cut it. And I doubt MF will take on new fresh debt to pay the bills. FDA success would have bailed them out with a higher PPS to dilute. So unfortunately I predict a nasty R/S in the near future. It is what it is. JMHO
Translation…bucillamine does not work on Covid-19.
Very interesting video, it tells me a lot, and says $RVVTF is far from done and does the PR update this morning. Also interesting that so many short sellers MM's are all over the L-2 data over playing their hand on a very red day. Even flippers world is and shorts are loading up the bid, heavy.
Interesting morning here. Every low life short seller MM is on L-2 molesting the ask trying to short and crash the stock but the longs are buying, and even PAUL moved his ask to $1, LMAO...
I started buying these early Christmas gifts already, and this price is steal of deal.
The so called bad news, is not really news, it just triggered a short MM raid that is failing. The good news I see is:
75% of the hospitalizations were in the Placebo group based on low dose for Bucillamine and 100% of the hospitalizations were from Placebo in the High dose Bucillamine trials.
"there were no deaths and four hospitalizations, of which three were from the placebo arm and one from the Bucillamine low dose group (300mg/day). No hospitalizations occurred in the Bucillamine large dose group (600mg/day), which was the dose suggested by the independent Data Safety Monitoring Board (“DSMB”) at the first interim analysis for the Post-dose selection phase of the Study. The one hospitalization event in the Bucillamine arm occurred in the low dose group (300mg/day), which was the dose abandoned after the first interim analysis per DSMB’s recommendation. Although the number of hospitalization events was small, it demonstrated a positive trend in the Post-dose selection phase of the Study. "
"However, based on preliminary analyses, the data demonstrated that for patients with oxygen saturation <96% at baseline, Bucillamine had a 29.1% improvement over placebo in time to normal oxygen saturation (SpO2)"
"Additional analyses of the Study data are ongoing, which could support certain strategic decisions on pursuing the development and commercialization of Bucillamine.
Based on the Study’s data analyzed to date, the Company is committed to advancing the clinical and commercial development of Bucillamine and is pursuing the following strategic initiatives"
They don't sound done to me. In fact they said:
Bucillamine 2.0: Reformulating Bucillamine in an intravenous and inhaled version to expand on its potential therapeutic utility targeting rare disorders such as ischemia-reperfusion injury (i.e. organ transplantation), acute respiratory distress syndrome, and potential medical countermeasures (i.e. terrorist attack with a biological, chemical, or radiological/nuclear material, or a naturally occurring emerging disease), that may come with regulatory incentives awarded by the FDA, such as emergency use authorization, orphan drug, fast track, and breakthrough therapy designations.
Pharmaceutical Partnerships: Work with interested pharmaceutical partners to pursue potential domestic and international regulatory approvals and new clinical studies for infectious, inflammatory and respiratory disorders.
Government Support: Seek out potential funding opportunities offered by, but not limited to, the Biomedical Advanced Research and Development Authority (BARDA), the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS).
We're basically done here. For me it doesn't pay to sell even though I lost my shirt. I will see what happens end of year to make a decision. Such a shame, so much promise. I guess another lesson learned from buying and holding a penny stock hoping to become rich, back to work I go.
“The Study did not achieve statistical significance on the clinical endpoints.”
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
https://finance.yahoo.com/news/revive-therapeutics-announces-results-phase-103000347.html
And now there is a Bucillamine video Jul 5, 2023
Bucillamine: A Unique Antirheumatic Drug with Different Properties and Possible Mode of Actions
that's about it
You obviously have not done any DD on PharmaTher. Check it out!
LOLOL....This sounds like the magic bullet theory. Is this all you got? PharmaTher is a 14 cent stock playing the same string investors along game MF is playing. You bet they're in the same building, like organized crime working together to pick your pocket. In 3 years you guys still haven't figured this out yet have you? Unbelievable.
Followers
|
340
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36602
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |